Table 1.
Interview participants and demographic information.
| Stakeholder Group | ||
| Provider | 10 | |
| Patient | 16 | |
| Diagnostic Lab | 8 | |
| Sex | ||
| Female | 20 | |
| Male | 14 | |
| Ethnicity/Race | ||
| Asian | 4 | |
| White | 29 | |
| More than One Race | 1 | |
| Age | ||
| 30–39 years | 4 | |
| 40–49 years | 8 | |
| 50–59 years | 14 | |
| Over 60 years | 8 | |
| Cancer Type * | Provider | Patient |
| Breast | 3 | 5 |
| Colorectal | 2 | 0 |
| Non-Small-Cell Lung Cancer | 5 | 3 |
| Prostate | 0 | 2 |
| Leukemia | 3 | 4 |
| Other | 4 | 5 |
| Drug^ | ||
| Cetuximab | 1 | 2 |
| Panitumumab | 0 | 0 |
| Trastuzumab | 1 | 5 |
| Pertuzumab | 1 | 0 |
| Ado-Trastuzumab Emtansine | 1 | 0 |
| Lapatinib | 1 | 0 |
| Trametinib | 2 | 0 |
| Dabrafenib | 2 | 3 |
| Crizotinib | 5 | 5 |
| Dasatinib | 3 | 2 |
| Imatinib | 2 | 0 |
| Bosutinib | 3 | 0 |
* Cancer diagnosis that patient received or provider diagnosed that led to inclusion in the study. ^ Cancer drug that patient received or provider diagnosed that led to inclusion in the study.